Émilie Meunier, Mélissa Aubin Vega, Damien Adam, Anik Privé, Mohammad Ali Mohammad Nezhady, Isabelle Lahaie, Christiane Quiniou, Sylvain Chemtob, Emmanuelle Brochiero
The acute exudative phase of acute respiratory distress syndrome (ARDS), a severe form of respiratory failure, is characterized by alveolar damage, pulmonary oedema, and an exacerbated inflammatory response. There is no effective treatment for this condition, but based on the major contribution of inflammation, anti-inflammatory strategies have been evaluated in animal models and clinical trials, with conflicting results. In COVID-19 ARDS patients, interleukin (IL)-1 and IL-6 receptor antagonists (IL-1Ra and IL-6Ra, kineret and tocilizumab, respectively) have shown some efficacy...
April 9, 2024: Experimental Physiology